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Abstract
Background: Approximately 1 in 5 women diagnosed with breast cancer are considered to have in situ disease, most
often termed ductal carcinoma in situ (DCIS). Though recognized as a risk factor for the development of more invasive
cancer, it remains unclear what factors contribute to DCIS development. It has been shown that inflammation contributes
to the progression of a variety of tumor types, and nuclear factor kappa B (NF-κB) is recognized as a master-regulator of
inflammatory signaling. However, the contributions of NF-κB signaling to tumor initiation are less well understood.
Aberrant
up-regulation of NF-κB activity, either systemically or locally within the breast, could occur due to a variety of commonly
experienced stimuli such as acute infection, obesity, or psychological stress. In this study, we seek to determine if
activation of NF-κB in mammary epithelium could play a role in the formation of hyperplastic ductal lesions.
Methods: Our studies utilize a doxycycline-inducible transgenic mouse model in which constitutively active IKKβ
is expressed specifically in mammary epithelium. All previously published models of NF-κB modulation in the
virgin mammary gland have been constitutive models, with transgene or knock-out present throughout the life
and development of the animal. For the first time, we will induce activation at later time points after normal
ducts have formed, thus being able to determine if NF-κB activation can promote pre-malignant changes in
previously normal mammary epithelium.
Results: We found that even a short pulse of NF-κB activation could induce profound remodeling of mammary ductal
structures. Short-term activation created hyperproliferative, enlarged ducts with filled lumens. Increased expression of
inflammatory markers was concurrent with the down-regulation of hormone receptors and markers of epithelial
differentiation. Furthermore, the oncoprotein mucin 1, known to be up-regulated in human and mouse DCIS, was
over-expressed and mislocalized in the activated ductal tissue.
Conclusions: These results indicate that aberrant NF-κB activation within mammary epithelium can lead to molecular
and morphological changes consistent with the earliest stages of breast cancer. Thus, inhibition of NF-κB signaling
following acute inflammation or the initial signs of hyperplastic ductal growth could represent an important
opportunity for breast cancer prevention.
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Background
How cancer starts is a topic of considerable debate. In
the case of breast cancer, many believe that changes in
the ductal or lobular epithelium begin subtly and then
progress along a continuum until they become malig-
nant and eventually metastatic [1]. Mirroring this pro-
gression are changes in the architecture and structure
of the ductal epithelium: an organized bilayer of cells
begins to exhibit atypia, hyperplasia, ductal occlusion,
and eventually advances to a chaotic mass [2]. This im-
plies that finding the earliest abnormalities in ductal
structure will help the clinician to intervene before the
accumulated effects become life-threatening. It is based
on this assumption that thousands of women are en-
couraged to undergo mammograms each year, and a
subset to undergo tissue biopsy as a result of detection
of radiographic abnormalities.
With an increased prevalence of screening, there has
also been an increase in the detection of early stage
lesions, many termed “ductal carcinoma in situ” (DCIS)
[3]. DCIS is considered one of the earliest forms of
breast cancer and is characterized by proliferating
ductal epithelial cells exhibiting atypia, but not yet
breaking through the basement membrane. Approxi-
mately 20 % of all breast cancer diagnoses in the United
States (about 60,000 cases per year) are deemed in situ
[4]. The presence of these early lesions within the
breast is recognized as a risk factor for invasive breast
cancer occurrence, so women are treated with aggres-
sive therapy such as lumpectomy or mastectomy some-
times followed by radiation [5]. However, the field has
yet to truly understand the natural history of DCIS [6].
It remains unclear what factors contribute to its devel-
opment and progression. If these factors could be
determined, could we inhibit them and prevent hyper-
plastic lesions from occurring? In addition, are there
specific signaling pathways that could be blocked to
prevent them from progressing? These are critical ques-
tions, the answers to which would affect thousands of
women each year.
Inflammation is recognized as a critical component for
the progression of a variety of cancers [7]. Nuclear Factor
Kappa-B (NF-κB) is a family of transcription factors that
regulate inflammatory signaling. The most widely-studied
members of this family are part of the canonical pathway,
where upstream signaling induces phosphorylation of the
Inhibitor of Kappa-B kinase-beta (IKKβ). This in turn
phosphorylates the Inhibitor of Kappa B alpha (IκBα), tar-
geting it for degradation. With the inhibitor gone, p65/
p50 heterodimers once held in the cytoplasm are free to
enter the nucleus and affect transcription of downstream
gene targets [8–11]. These include genes that participate
in a wide range of cellular processes such as proliferation,
apoptosis, angiogenesis, and cytokine release. It has been
shown that NF-κB activity within breast tissue can in-
crease due to stimuli such as obesity, acute infection, or
physiological stress [12–14].
In a previous mammary development study, Brantley et.
al found that IκBα knock out (KO) transgenic mouse epi-
thelium develops abnormally, with hyper-branched struc-
tures and filled ductal lumens [15]. This was the first hint
that there might be a link between NF-κB activation and
the initiation of aberrant growth in breast epithelium.
Though we and others have previously drawn a connection
between NF-κB activation and mammary tumor progres-
sion, these experiments were all performed in combination
with strong oncogenic or carcinogenic tumor models
[16–19]. In contrast, the study noted above attempted
to model the consequences of NF-κB activation within
developing breast epithelium in the absence of any other
tumorigenic stimuli.
In the current work, we use a novel doxycycline (dox) in-
ducible transgenic mouse model to acquire deeper insights
into whether activated NF-κB signaling in the mammary
epithelium could play a role in the formation of hyperplas-
tic breast lesions. In these transgenics, NF-κB is activated
through expression of a constitutively active IKKβ (cIKKβ)
in mammary epithelial cells [12]. Our system not only di-
rects activation to a specific cell type (mammary epithe-
lium), but it allows temporal control of that activation. All
previously published models of NF-κB modulation to inves-
tigate development of the virgin mammary gland have been
constitutive models, with transgene or KO present through-
out the life and development of the animal. For the first
time, we can induce activation at later time points after
normal ducts have formed, thus being able to determine if
NF-κB activation can promote pre-malignant changes in
previously normal mammary epithelium. Through these
studies, we show that NF-κB activation in the virgin mam-
mary gland can lead to rapid molecular and morphological
changes consistent with early mammary tumorigenesis,
including hyperproliferation of ductal epithelial cells,
filling of ductal lumens, macrophage infiltration, and
increased expression and mislocalization of the onco-
gene Mucin 1 (MUC1).
Methods
IKMV mouse model
All animal experiments were approved by the Vanderbilt
University Institutional Animal Care and Use Commit-
tee. Transgenic mice containing the NF-κB activating
(tet-O)7-FLAG-cIKK2 construct [20] were mated with
mouse mammary tumor virus-reverse tetracycline trans-
activator (MMTV-rtTA) mice [21] (gift from Dr. L.
Chodosh, School of Medicine, University of Pennsylvania,
Philadelphia, PA). This cross produced pups carrying both
transgenes which were designated IKMV, as previously de-
scribed [12]. Littermates lacking one or both transgenes
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were used as controls. All mice were on an FVB strain
background. IKMV females (or littermate controls) were
maintained on normal water until transgene activation
was required. At the appropriate experimental time point,
both IKMV and control virgin females were treated with
freshly prepared doxycycline (dox) (Sigma-Aldrich), given
ad libitum in drinking water (1 – 2 g/L). Sucrose (5 %)
was also added to decrease the bitter taste of dox water. A
red bottle was used to prevent light-induced dox degrad-
ation and water was replaced twice per week.
TransAM ELISA
Nuclear extracts from whole mammary tissue were ob-
tained using our previously described methods [22]. Halt
protease/phosphatase inhibitor cocktails (Pierce) were
added to lysis buffers. Following extraction, protein con-
centration was assessed using a Bradford assay (BioRad).
TransAM ELISA (Active Motif) was completed according
to manufacturer’s instructions using the anti-p65 antibody
provided in the NF-κB family member kit (Cat #43296). 8
micrograms of nuclear extract were added to each well,
and samples were run in duplicate. A total of 4 control
samples and 4 IKMV samples (6 week virgin, 3 days
dox treated time point) were compared for the graph
and statistics.
Mammary gland transplant
General procedures for isolation and transplantation of
mammary epithelial tissue have been demonstrated previ-
ously [23]. Details of our protocol were also described in a
previous manuscript [15]. With regard to the current stud-
ies, IKMV donor mammary tissue from 3–4 week old do-
nors was transplanted into the cleared fat pad of the left
inguinal mammary gland of 3 week old FVB wild type re-
cipient females. Donor tissue taken from a littermate con-
trol was transplanted into the contralateral cleared fat pad.
Tissue was collected and transplanted on the same day (no
cryopreservation). After transplant, recipient mice were
monitored through a 3 day recovery period during which
they remained on normal water. 72 h post-transplant, the
mice began dox treatment (2 g/L), which was continuous
until sacrifice. The mammary glands were analyzed 3 or
4 weeks after transplantation.
Mammary whole mount staining
Number 4 inguinal mammary glands of dox-treated mice
were collected and spread on microscope slides at the
time of sacrifice. Glands were then fixed overnight in
formalin at 4 °C followed by haematoxylin staining as
previously described [22]. Images were captured using a
dissecting microscope and Canon Powershot A590
camera. If mice underwent transplant, the fat pad in
which the transplanted tissue had been inserted was
collected and placed on a microscope slide. This was
then prepared and imaged in the same way as the intact
IKMV and control glands.
TEB size quantification
Whole mount images were analyzed using MetaMorph
software (Molecular Devices). A photo was taken of a
standard ruler at the time the whole mount images were
captured, using identical parameters and magnification.
After images were loaded into MetaMorph, a circle was
drawn around the TEB. Using the ruler photo for calibra-
tion, the software translated each region into an area meas-
urement. The same calibration was applied to all images
analyzed. 5 control and 6 IKMV transplanted glands were
used for comparison of TEB size. 5 TEB’s from each whole
mount were measured and values averaged.
Branching quantification
Branching was quantified using Photoshop CS4 software
(Adobe). Whole mounts of IKMV and control trans-
planted glands, treated with dox for 3 weeks, were imaged
at the same session and using the same magnification.
Photos were then loaded into the program and a grid of
75 mm squares was digitally overlaid onto each image.
The number of bifurcations observed in each square was
manually counted. At least 8 individual squares were
counted per gland and the values averaged. 4 separate
control transplanted glands and 4 IKMV transplanted
glands were compared for quantification.
Histology (H&E’s)
Number 4 inguinal mammary glands (intact or trans-
planted fat pads) were fixed in 10 % formalin overnight
at 4 °C. The glands were then dehydrated in a graded
ethanol series followed by xylenes and embedded in par-
affin. 5 μm sections were prepared and stained with
haematoxylin and eosin (Vanderbilt University Medical
Center, Allergy, Pulmonary, and Critical Care Medicine
Immunohistochemistry Core).
Area of duct quantification
To quantify the area of each duct, H&E stained slides
were used. Terminal end buds (found at the leading
edge of the 6 week old glands) were excluded from all
analyses. Images of ducts were captured using a Zeis
Axioplain 2 microscope at 20X magnification. After
capture, images were analyzed using MetaMorph soft-
ware (Molecular Devices). The outer edge of each duct
was traced using the drawing feature to form a polygon.
The area of the polygon was then determined based on
a calibration scheme (pixels to micrometers) previously
performed by the Cancer Biology Microscopy Core
using the 20X objective and MetaMorph software. This
resulted in an area measurement for each duct in mi-
crometers squared. If a lumen was present in the duct,
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the edges of the lumen were traced to form a second
polygon. This area measurement was subtracted from
the first to yield the area actually containing cells in
each duct. 3 control glands and 3 IKMV glands from
the each time point (6 week virgin or 16 week virgin)
were analyzed. A minimum of 8 ducts per gland were
measured.
Immunohistochemistry
PCNA staining was completed using formalin fixed,
paraffin embedded tissue. Slides were deparaffinized
using xylenes and a graded ethanol series and antigen
retrieval was completed using citrate buffer (pH 6) and
steam heat. After blocking with 1 % BSA, slides were
incubated with Biotin-conjugated PCNA monoclonal
antibody (Life Technologies) at a 1:100 dilution for
1.5 h at room temperature. VECTASTAIN Elite ABC
Kit (Mouse IgG) and VECTOR NovaRED Peroxidase
(HRP) Substrate Kit were used for visualization (Vector
Laboratories, Inc.), and slides were counterstained with
haematoxylin. Images of 6 ducts per slide were cap-
tured using a Zeis Axioplain 2 microscope at 20X mag-
nification. Images were then loaded into MetaMorph
software (Molecular Devices) for quantification. Posi-
tive cells were manually counted and the number of
positive cells normalized to the total area of each duct
(area calculated as described above). Mammary glands
from 3 control and 3 IKMV glands were used for quan-
tification and 6 ducts per gland were counted. TEB’s
were excluded from all analyses. F4/80 staining was
completed by the Vanderbilt Translational Pathology
Shared Resource using a rat anti-mouse monocolonal
antibody against F4/80 (CI:A3-1) (Novus Biologicals).
Images were captured using a Zeis Axioplain 2 micro-
scope at 20X magnification.
Immunofluorescent staining was completed using
formalin fixed, paraffin embedded mammary tissue sec-
tions and primary antibodies against: MUC1 (AbCam);
Cytokeratin-5 (Covance); Cytokeratins 8/18 (RDI-Fitz-
gerald); Smooth muscle actin (SMA) (CalBiochem);
FLAG (Sigma); Ki-67 (Abcam); ERα (Thermo Fisher);
and phospho-p65 (ser536) (Cell Signaling). The staining
protocol was similar to above, but required blocking
with 2 % BSA and goat serum, and addition of appro-
priate secondary antibodies tagged with either Alexa
Fluor 488 or Alexa Fluor 594 (both Life Technologies).
Slides were coverslipped using Molecular Probes Pro-
longGold antifade reagent (Life Technologies) to pre-
serve fluorescence. Images were then captured using
either a Zeis Axioplain 2 microscope or a LSM 510
Meta confocal microscope in the Vanderbilt Univer-
sity Medical Center Imaging Core. Either TO-PRO-3
(Life Technologies) or DAPI (Sigma) were used as nu-
clear stains.
Flow cytometry
Following sacrifice, mammary glands #2-4 were har-
vested for analysis. Lymph nodes of the #4 glands were
removed prior to collection. Glands were minced and
placed in 3 mL’s of DMEM/F12 containing 3 mg/mL of
Collagenase A (Roche) and 100 units/mL Hyaluronidase
(Sigma). Glands were incubated in digestion media over-
night at 4 °C, followed by 2 h of incubation at 37 °C the
following morning. After digestion, cells were pelleted
and the fatty layer at the top of the supernatant was
discarded. After straining cells through a 70 micron fil-
ter, red blood cells were lysed using ACK buffer.
Remaining cells were then washed and counted using a
hemocytometer. Cells were blocked with anti- mouse
CD16/CD32 antibody (eBioscience) before staining with
anti-mouse antibodies: CD45 (30-F11) (eBioscience) and
F4/80 (BM8) (Life Technologies). DAPI nuclear stain was
used to determine viability. Analysis was performed on an
LSRII cytometer with DIVA software (BD Biosciences).
Gating strategy can be found in Additional file 1. Values
for the graph in Fig. 7b were obtained by taking the total
number of CD45+F4/80+ positive cells for each sample
and dividing that value by the total number of viable
cells in the sample (DAPI negative).
RNA isolation and RT-PCR
Mammary gland total RNA was extracted using Trizol
(Invitrogen) and the RNeasy Mini Kit (Qiagen), as previ-
ously described [12]. RT-PCR was utilized to detect expres-
sion of the FLAG-tagged cIKKβ transgene (annealing
temperature of 58 °C and a 35 cycle program). For all other
gene targets, qRT-PCR was performed using the Applied
Biosystems Stepone Plus Real-Time PCR system and SYBR
Green PCR Master Mix (Applied Biosystems) (annealing
temperature of 60 °C and a 40 cycle program). All primer
sequences used are contained in Table 1. Each primer pair
was tested and melt curves analyzed to ensure that only a
single amplicon was generated. All experimental and con-
trol samples were assayed in triplicate for target gene or
GAPDH (reference gene). The average of the three CT
values was used as “CT” for each sample. For graphical rep-
resentation, target gene CT values (A) and GAPDH CT
values (B) were both expressed as exponents of 2, and data
represented as the ratio of 2A/2B, or 2(A - B). The exception
is Fig. 7a, which contains qRT-PCR data graphed as log fold
change. These values were produced using the 2-Δ(ΔCT)
comparative method [24] and then GraphPad Prism
software was used to put those values on a log scale. P
values for the statistical comparison of the data in
Fig. 7a are in Table 2.
Data analysis
Statistical analyses were performed using GraphPad
Prism (GraphPad Software Inc.). In each case, paired t-
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statistics with p-value < 0.05 were used to determine
whether the values in IKMV tissue were significantly
different from those in control. Data are plotted graph-
ically as mean vertical bars representing standard error
(except for Fig. 7a). The height of the bars in Fig. 7a
represent average fold change, as described above, and
do not contain standard error bars.
Results
IKMV transgenic mouse model targets expression of
cIKKβ specifically to mammary epithelium
Previously, our group has studied the activation of NF-κB
in mammary tissue in vivo using IκBα knock-out mice
[15]. In these transgenics, deletion of the inhibitor is sys-
temic and activity through the canonical pathway is in-
creased within every tissue, causing mortality by day 9
post birth [25]. However, transplant of mammary tissue
from 6 day old female pups into wild type donors allowed
us to observe the effects of NF-κB activation during pu-
bertal mammary gland development. Using this model, we
found an increase in lateral ductal branching and perva-
sive intraductal hyperplasia in the IκBα knock-out recon-
stituted glands. This was the first indication that aberrant
NF-κB activation could lead to dramatic changes in ductal
growth. As in most mammary transplant methods, stro-
mal and epithelial components were co-transplanted into
recipients. Because IκBα had been deleted in both of these
components, it was impossible to determine whether it
was the epithelial derived NF-κB activation that caused
the resulting phenotype. To address this and to enable
specific temporal regulation of the increased activation of
NF-κB, we developed a doxycycline (dox) inducible model
which would target activation specifically to mammary
epithelium. This model requires two transgenic compo-
nents: tet-O-cIKKβ mice are combined with MMTV-rtTA
transgenics to produce double transgenic mice that we
have termed “IKMV” (Fig. 1a). RT-PCR of whole mam-
mary homogenates confirms the FLAG-tagged cIKKβ
transgene is dox-inducible. Upon dox-treatment, trans-
gene expression was evident in the */* double transgenic
IKMV mammary, but absent in dox-treated, single trans-
genic control mice (−/*). Double transgenic */* IKMV
mice that did not receive dox-treatment showed no de-
tectable transgene expression (Fig. 1b). Thus, in all
Table 1 A comprehensive list of all real time primer sequences used in our studies
Gene Forward (5'-3') Rev (5'-3')
GAPDH TGAGGACCAGGTTGTCTCCT CCCTGTTGCTGTAGCCGTAT
CIKK2-FLAG GGAGCTCCACCGCGGTGCGG TCAGGGACATCTCGGGCAGC
Cyclin bl AAGGTGCCTGTGTGTGAACC GTCAGCCCCATCATCTGCG














Table 2 Statistical significance values for qRT-PCR shown as fold
change in Fig. 7a
Gene Samples Assayed (control, IKMV) p value
CXCL1 n = 3, n = 4 0.0067
ILl-β n = 6, n = 6 0.0241
TNF-α n = 6, n = 7 0.0336
Cox-2 n = 6, n = 7 0.0593
CCL-2 n = 3, n = 3 0.0159
IL-12 n = 3, n = 3 0.0169
RANK n = 5, n = 7 0.0100
ERα n = 6, n = 7 0.0424
Prolactin-R n = 6, n = 7 0.0100
Progesterone-R n = 6, n = 7 0.0053
Elf 5 n = 6, n = 6 0.0031
Csn2 n = 4, n = 4 0.0038
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subsequent studies, “IKMV” refers to the double trans-
genic mice and “control” refers to littermates lacking
one or both transgenes, which behave as wild type
mice. To confirm the ability of the transgene to activate
NF-κB activity, TransAM ELISA was completed using
the nuclear fraction of mammary tissue lysates. This
showed that there is increased binding of nuclear p65 to
the NF-κB DNA consensus sequence following transgene
induction (Fig. 1c).
Mammary epithelial expression of cIKKβ during ductal
development results in enlarged terminal end-buds,
increased lateral branching, and hyperplasia
After validating the IKMV transgenic system, we used
the mammary transplant model to produce samples that
could be directly compared to our studies using the IκBα
KO mice. To do this, IKMV donor mammary tissue was
transplanted into the cleared fat pad of 3 week old FVB
wild type recipient females. Donor tissue taken from a
littermate control lacking one or both transgenes was
transplanted into the contralateral cleared fat pad. Re-
cipient mice were dox-treated continuously following
the transplant, and glands were analyzed at both 3 and
4 week post-transplant time points. Haematoxylin stained
whole mounts of the tissue reveal that the IKMV ductal
tree has on average three times the number of lateral
branch points as the control transplants after 3 weeks of
growth (Fig. 2). The IKMV ducts are not only hyper-
branched, but also hyperplastic, as H&E staining clearly
shows filled lumens and increased cell density throughout
the transgenic ducts. In addition, we found that the ter-
minal end-buds of the IKMV glands were larger than the
controls. These studies definitively show that epithelial
specific NF-κB activation during ductal branching mor-
phogenesis results in abnormal branching and hyperplas-
tic ductal growth.
Short term activation of NF-κB results in dramatic
morphological changes within previously normal
mammary ductal structure
In our transplant studies, outgrowth of the mammary
ducts and NF-κB activation had been simultaneous, start-
ing when the hosts were 3 weeks of age. In order to better
model early tumorigenesis without the overlay of develop-
mental abnormalities, we induced NF-κB signaling after a
subset of normal ductal structures had already formed. To
do this, we took 6 week old virgin, intact IKMV and con-
trol females and dox-treated them for 3 days prior to col-
lection. Surprisingly, we found that after this short pulse
of transgene induction, striking changes had occurred
throughout the IKMV ductal structure. The lumens of the
IKMV ducts were completely filled with cells and the
ducts were significantly enlarged (Fig. 3a,b). This pheno-
type is fully penetrant and occurs in 100 % of the ducts
throughout the IKMV glands. As an added control, non-
dox treated, double transgenic IKMV females were col-
lected at the same 6 week old, virgin time-point. Mammary
tissue from these untreated controls appeared normal,
with no lumen-filling or hyperplastic ducts (Fig. 3c).
Fig. 1 Transgenic mouse model targets expression of cIKKβ specifically to
mammary epithelium. a Diagram shows crossing of two transgenic
strains necessary to generate the double transgenic (*/*) IKMV
mouse model with doxycycline inducible transgene expression.
Littermates lacking either one or both transgenes (*/-, −/*, or −/−)
were used throughout our studies as littermate controls. For
characterization, IKMV and control littermates were treated with
doxycycline (2 g/L) for 3 days and mammary tissue collected for
the following assays: b RT-PCR of whole mammary homogenates
confirms the FLAG-tagged transgene is dox-inducible. Upon
dox-treatment, the transgene was expressed in the */* double
transgenic IKMV animals, but absent in dox-treated, single transgenic
control mice (−/*). Double transgenic */* IKMV mice that did not
receive dox-treatment showed no detectable transgene expression.
c TransAM ELISA assay using IKMV and control mammary nuclear
homogenates shows that nuclear p65 in IKMV samples actively
binds the NF-κB DNA consensus sequence (n = 4 control, n = 4
IKMV samples; **p = 0.0069)
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Fig. 2 (See legend on next page.)
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(See figure on previous page.)
Fig. 2 Expression of cIKKβ in transplanted mammary epithelium results in intraductal hyperplasia. Mammary tissue from 3–4 week old IKMV donors was
transplanted into the cleared fat pad of the #4 mammary gland of 3 week old FVB recipients. Tissue from control littermates was transplanted
into the contralateral #4 gland. After a 72 h recovery period, mice were placed on dox treatment (2 g/L), which was continuous until sacrifice at 3
or 4 weeks post-transplant. a Haematoxylin stained whole mounts of mammary fat pads after 3 weeks of growth in recipient mice
reveal increased lateral branching of IKMV tissue. b Higher magnification highlights swollen end buds in IKMV. Hyperplasia of the IKMV
ducts is evident in images of H&E stained tissue using c 10X and d 20X objectives. e Whole mounts of mammary tissue after 4 weeks of
growth indicate that IKMV tissue continues to fill fat pad with hyperplastic tissue. The observed phenotype was quantitatively assessed
through: f quantification of terminal end bud (TEB) size (n = 5 control, n = 6 IKMV glands, **p = 0.0071) g quantification of the number of
lateral branch points per field (n = 4 control, n = 4 IKMV glands, *p = 0.0416)
Fig. 3 Short term activation of NF-κB in mammary epithelium leads to ducts with filled lumens. Intact 6 week old virgin IKMV and control littermates
were dox-treated (2 g/L) for 3 days prior to sacrifice. a Haematoxylin stained whole mounts of control and IKMV glands reveal changes in IKMV ducts.
In H&E stained sections (below), we observed a complete occlusion of IKMV ducts throughout the gland. b Increased size of individual IKMV ducts is
apparent in 20X images with calibration bars (150 μm). Multiple measurements of duct area across samples are quantified at right (n = 3 control, n = 3
IKMV glands, total of 65 individual ducts were measured; *** p < 0.001). c Double transgenic IKMV virgin females were kept on normal water at the
6 week virgin time point and collected 3 days later along with the dox-treated cohort. Images of H&E stained mammary tissue show ducts of untreated
controls have normal morphology, with no lumen-filling or hyperplastic growth (10X magnification at left, 20X at right)
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This confirmed that the phenotype in the dox-treated
IKMV mice occurred within the 3 day induction window.
Upon observing such a dramatic filling of the IKMV
ducts, we endeavored to determine whether the cells
within the ducts were epithelial. To do this, we com-
pleted immunofluorescent staining for the luminal
epithelial marker cytokeratin 8/18 (CK8/18). This re-
vealed that many of the cells filling the lumens stain
positive for this marker (Fig. 4a). In addition, FLAG-
tagged transgene expression was found throughout the
aberrant ducts in IKMV glands (Fig. 4b). Since transgene
expression is specific to MMTV-rtTA expressing mam-
mary epithelial cells in the IKMV system, this again sug-
gests that many of the cells filling the ducts are
epithelial. Finally, we wanted to confirm that the trans-
gene expression was indeed driving NF-κB activation
within the epithelium at the 3 day time point. Using im-
munofluorescent staining, and high magnification images,
we observed cytoplasmic localization of the transgene
within mammary epithelial cells resulting in robust nu-
clear localization of phospho-p65 (ser 536) (Fig. 4b).
As 6 week old virgin mice are still undergoing puberty,
the mammary tissue may be responding to a higher level
of hormonal stimulation than quiescent, adult glands. To
determine if the phenotype would also occur in adult
mice, we treated 16 week old virgin IKMV and control fe-
males with dox for 10 days. Upon collection, we saw that
the IKMV ducts were significantly larger than the control
ducts in cross sectional area and had indeed become filled
with cells (Fig. 5). This indicated that the notable changes
in the IKMV ductal structure after a short-term induction
of NF-κB activity were not dependent on puberty-related
physiological factors.
Cells filling the abnormal ducts are highly proliferative
Lumen-filling can be the result of decreased apoptosis
and/or increased proliferation and NF-κB signaling plays a
role in both of these cellular processes [26]. To determine
Fig. 4 Many cells within aberrant ducts are epithelial, transgene-expressing, and have high levels of NF-κB activation. 6 week old virgin IKMV and control
littermates were dox-treated (2 g/L) for 3 days prior to sacrifice. a Immunofluorescent staining of control and IKMV tissue reveals that IKMV ducts
are filled with CK8/18 positive luminal epithelium. CK5 and SMA were used as markers of basal/myoepithelium. b Separate staining shows that
the FLAG-tagged cIKKβ transgene is expressed by cells within the IKMV hyperplastic ducts (red, FLAG stain). In addition, high magnification images of
ductal tissue from IKMV and control littermates confirmed that the transgene is localized appropriately within the cytoplasm of IKMV mammary epithelium
and is driving concurrent nuclear localization of phospho-p65 (green)
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the mechanism most relevant to the rapid filling of the
IKMV ducts, we assessed the mammary tissue from
3 day dox treated IKMV and control mice to detect
changes in apoptosis or proliferation. To quantify apoptotic
cells, we stained the tissue with caspase-3, but found no
significant change in the number of caspase-3 positive cells
in IKMV vs. control tissue (data not shown). To assess pro-
liferation in the glands, we stained for proliferating cell nu-
clear antigen (PCNA) (Fig. 6a-c). This revealed a profound
increase in the number of proliferating cells within the
IKMV ducts. All of the enlarged ductal structures con-
tained PCNA positive cells, indicating that proliferation is
the principle mechanism by which the ducts become filled
with epithelium in such a short span of time.
Next, we looked for molecular markers of increased epi-
thelial proliferation present in the IKMV glands. Cyclin
b1is known to induce cellular transition from G2 to M
phase and is often overexpressed in human breast malig-
nancies [27]. Quantitative PCR (qRT-PCR) revealed in-
creased mRNA expression of cyclin b1 in IKMV mammary
tissue (Fig. 6d). Furthermore, expression of the mitotic in-
hibitor p18INK4c (CDKN2C) was significantly decreased in
IKMV tissue (Fig. 6e). This change is consistent with the
observed phenotype, as p18INK4c normally functions to re-
strain luminal progenitor cell expansion and inhibit lu-
minal tumorigenesis in the mammary gland [28].
To further confirm that it was truly epithelial cells under-
going proliferation within the IKMV ducts, we co-stained
Fig. 5 Abnormal ducts induced in fully adult, virgin glands through activation of NF-κB in mammary epithelium. 16 week old adult, virgin IKMV and
control females, which were previously untreated, were given dox (1 g/L) for 10 days prior to sacrifice. A subtle enlargement of ducts can be
seen in haematoxylin stained whole mounts (left panels). The phenotype is more apparent in H&E stained sections (100 μm calibration bar) (right
panels). IKMV ducts are filled with cells and significantly larger than the controls. Size of ducts is quantified below images (n = 3 control and n = 3
IKMV glands, total of 64 ducts were measured; ***p = 0.0003)
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Fig. 6 (See legend on next page.)
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control and IKMV mammary tissue (collected after 3 days
of dox treatment) with the proliferative marker Ki-67 and
the luminal epithelial marker CK8/18 (Fig. 6f). Ki-67 stain-
ing confirmed our earlier findings using the PCNA stain,
as nuclear Ki-67 was observed in cells throughout the
IKMV ducts. A number of these proliferating cells were
also positive for CK8/18 (double positive cells indicated by
arrows, Fig. 6f).
Increased expression of inflammatory markers in IKMV
mammary is concurrent with the down-regulation of
hormone receptors and markers of epithelial
differentiation
Our results show that activation of NF-κB in mammary
epithelium results in a rapid proliferative response and in-
duces a hyperplastic ductal structure. Because NF-κB sig-
naling can drive downstream expression (and sometimes
repression) of hundreds of gene targets, we wondered what
other molecular changes were occurring after NF-κB acti-
vation in the mammary ducts and how they could be
mediating the observed phenotype. To achieve this, we
completed a panel of qRT-PCR assays (Fig. 7a). Our ana-
lysis revealed that downstream read-outs of inflammatory
signaling, such as CXCL1, IL-1β, TNF-α, and Cox-2, were
significantly increased in the IKMV tissue. Interestingly, in-
creased expression of many of these products (IL-1β, TNFα,
and Cox-2) has been implicated in previous studies to con-
tribute to mammary hyperplasia and tumorigenesis [29–
31]. In addition, our analysis revealed a small but significant
increase in the expression of Receptor Activator of NF-κB
Kinase (RANK) in the IKMV mammary gland. Previous
studies have shown that increased signaling through
RANK/RANK-L in the mammary gland can lead to expan-
sion of the epithelium, disruptions in differentiation, and
disorganization of the basal/luminal structure. Also up-
regulated were genes associated with an influx of inflamma-
tory cells, specifically macrophages. CCL2 is a macrophage
chemoattractant, and its expression was increased in the
activated tissue. Accordingly, we found an increased per-
centage of F4/80 positive cells within the IKMV mammary
tissue via flow cytometry analysis (Fig. 7b). Immunohisto-
chemistry for F4/80 revealed that in control samples, mac-
rophages are sparse and localized along the outer edge of
the ducts, as expected. In the IKMV tissue, the F4/80
positive cells appear both around the outer edge and on the
inside of the ducts, interspersed between the hyperplastic
epithelium (Fig. 7c). We also detected an increased level of
IL-12 transcript in the IKMV tissue, indicating that the re-
cruited macrophages are likely more aligned with a classic-
ally activated phenotype.
Converse to the up-regulation of these inflammatory
components, we observed decreased hormone receptor
expression in the IKMV mammary, including lower
levels of estrogen receptor alpha (ERα), progesterone re-
ceptor, and prolactin receptor. Immunofluorescent staining
reveals decreased nuclear localization of ERα in IKMV
ducts (Fig. 7d). These decreases suggest that the prolifera-
tive response cannot be explained by increases in hormo-
nal signaling. We also observed a striking decrease in the
expression of β-casein (Csn2), a marker of mammary epi-
thelial differentiation. In addition, expression of Elf-5, a key
regulator of mammary epithelial differentiation, was also
decreased in IKMV epithelium. Deletion of Elf-5 can lead
to disorganized mammary structures and collapsed lu-
mens, suggesting that this decrease in expression could be
playing a role in the observed phenotype [32].
Pathological review of IKMV tissue confirms diagnosis of
low-grade DCIS
To determine the staging of the IKMV ductal abnormal-
ities, the H&E stained sections were analyzed by Dr.
Thomas Stricker MD/PhD, pathologist at Vanderbilt Uni-
versity Medical Center. Dr. Striker observed that the ducts
in the IKMV mice were expanded, containing mildly atyp-
ical cells with increased nuclear-cytoplasmic ratio, chroma-
tin condensation, nuclear membrane abnormalities, and
nucleoli. Furthermore, he found that cells in the glands
were well spaced out with few overlapping nuclei and that
there were increased numbers of apoptotic cells. Taken to-
gether, he concluded that these findings are consistent with
a diagnosis of low-grade DCIS.
MUC1 oncoprotein is up-regulated and mislocalized in
IKMV mammary epithelium
To further strengthen correlations between the IKMV
phenotype and DCIS, we analyzed the expression and
localization of Mucin 1 (MUC1). This protein is normally
expressed on the apical surface of mammary epithelium
(See figure on previous page.)
Fig. 6 Cells filling abnormal IKMV ducts are highly proliferative. 6 week old virgin IKMV and control littermates were dox-treated (2 g/L) for 3 days
prior to sacrifice. PCNA staining of mammary tissue reveals increased proliferation in the IKMV ducts as compared to controls, shown in both a 10X and
b 20X images (positive staining is dark brown). c This increased number of PCNA positive cells/duct was quantified (counts were normalized to area of
each duct; n= 3 control, n= 3 IKMV glands were used for quantification and 6 ducts per gland were counted; ***p < 0.0001). d,e qRT-PCR analysis shows
increased expression of cyclin b1 and decreased expression of p18INK4c following activation of NF-κB in mammary epithelium (n= 6 control, n= 7 IKMV
samples run for cyclin b1; *p= 0.0210; n= 3 control, n= 4 IKMV samples run for p18IKN4c; *p = 0.0064). f Immunofluorescent staining for Ki-67 (green,
nuclear) confirms that cells within the IKMV ducts are actively cycling. Many of the proliferating cells co-stain with CK8/18 (red, cytoplasmic), indicating
that the luminal epithelium is driven to proliferate upon activation of NF-κB. Note that the far right image is a magnification of the white box in the
center image. White arrows indicate double positive Ki-67/CK8/18 cells
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where, similar to other mucins, it plays a role in host
defense against pathogens. Beyond this role in normal
physiology, MUC1 is considered an oncoprotein, as its
overexpression can functionally drive malignant trans-
formation in breast epithelium [33]. When luminal epithe-
lial cells lose their polarity due to stress or transformation,
MUC1 can be expressed around the entire cell membrane
rather than staying localized to the apical surface. This re-
positioning of MUC1 has been noted in both ductal
hyperplasia with atypia and in DCIS of the breast [34]. We
analyzed our 6 week virgin, 3 day dox treated samples for
MUC1 expression and observed a significant up-regulation
of MUC1 in IKMV tissue via qRT-PCR (Fig. 8a). Further,
we completed immunofluorescent staining and found that
IKMV ducts contained MUC1 positive cells dispersed
throughout the filled lumens (Fig. 8b). These positive cells
displayed MUC1 staining around the entire cell membrane.
This was in contrast to the control ducts, which had
Fig. 7 Aberrant activation of NF-κB in mammary epithelium induces downstream signaling consistent with early tumorigenesis. RNA was isolated from
mammary glands of IKMV and control mice after 3 days of dox treatment (6 week time point). a qRT-PCR for a variety of gene targets revealed increased
expression of inflammatory markers as well as decreased expression of hormone receptors and markers of epithelial differentiation (bars represent log
fold change of IKMV vs. control; p values for each comparison can be found in Table 2. b Flow cytometry indicates there is an increased percentage of
CD45+/F4/80+ macrophages in mammary glands following NF-κB activation, and c immunohistochemistry reveals that F4/80 positive macrophages have
infiltrated the mammary ducts of IKMV mice (positive cells are dark brown). d Immunofluorescent staining reveals decreased nuclear localization of ERα
in IKMV ducts (red; dense and nuclear in control epithelium)
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appropriately localized MUC1 along the apical surface of
each lumen.
Discussion
In this study, we have modeled specific activation of NF-
κB signaling in virgin mammary epithelium and demon-
strated a variety of downstream morphological and mo-
lecular consequences.
Transplant studies using IKMV transgenic tissue revealed
that aberrant activation of NF-κB during ductal outgrowth
leads to hyper-branched, hyperplastic ductal structures.
The resulting phenotype is strikingly similar to the studies
completed using IκBα KO tissue even though the current
model uses a different means of pathway intervention (con-
stitutive IKKβ). In addition, further analyses in both models
indicated that the expanded epithelium in activated tissue
was the result of increased proliferation, not decreased
apoptosis. Because the IKMV transgene is epithelial spe-
cific, we definitively show that aberrant NF-κB signaling
originating within the epithelium can drive these morpho-
logical changes. It has been suggested that hyperplastic
growth of ductal tissue is the result of stromal changes and
that the epithelium is influenced to become malignant be-
cause its environment has provided a permissive niche [35].
In future studies, it would be intriguing to determine if the
observed alterations in epithelial signaling and structure
could be induced by starting the cross-talk from the other
direction and initiating NF-κB activation specifically in
the stroma. One published study suggests this may be
the case: when AEBP1, an inflammatory mediator, was
overexpressed in macrophages and adipocytes, it was
able to activate NF-κB activity in the mammary gland
and led to alveolar hyperplasia [36].
After completing the transplant studies, we hypothe-
sized that NF-κB-driven hyperplastic growth might play a
role in the formation of hyperplastic breast lesions, or
DCIS. This could now be formally tested using the tem-
poral control provided in the IKMV model. We found that
we could establish a network of normal ducts in 6 week
old virgin females, and then induce hyperplasia through
3 days of aberrant NF-κB signaling. In addition, similar
changes occurred upon activation of the epithelium in a
fully adult, 16 week old gland. One striking aspect of this
phenotype is its rapid induction. Though aberrant signal-
ing through other cell-signaling pathways is certainly able
to induce mammary ductal hyperplasia, it is often over a
period of weeks or months, not days. A noted exception is
activation of FGF-receptor 1 (FGFR-1) in mammary
epithelium. Welm et al. induced FGFR-1 transgene acti-
vation at the 6 week virgin time point and observed
rapid formation of hyperplastic ductal structures ac-
companied by increased inflammatory signaling and
macrophage recruitment [37]. It was later shown that
IL1-β secretion by the recruited macrophages was play-
ing a significant role in the hyperplastic growth, as
blocking IL1-β or depleting macrophages abrogated the
effects of FGFR-1 signaling [29]. They note that IL1-β
treatment of mammary epithelial cells induces NF-κB
activation, which suggests that the phenotype we ob-
serve in the IKMV model could be mediated, at least in
Fig. 8 MUC1 oncoprotein is up-regulated and mislocalized in IKMV mammary epithelium. RNA was isolated from mammary glands of IKMV and control
mice after 3 days of dox treatment (6 week time point). a The hyperplastic IKMV ducts have increased expression of MUC1 via qRT-PCR (n = 5
control, n = 6 IKMV samples; *p = 0.0119). b Staining for MUC1 indicates that it is properly localized to the apical surface of luminal epithelium in
control ducts but it has become repositioned to the entire cell membrane in many of the cells within the IKMV hyperplastic ducts (red staining is
MUC1, blue is DAPI; 40X images are shown; images at bottom are magnified to show detail)
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part, by paracrine IL1-β secretion. While the timing is
similar, hyperplastic growth in the FGFR-1 model is the re-
sult of increased lateral budding of the epithelium, whereas
the IKMV model exhibits lumen-filling and duct enlarge-
ment. Thus, there are likely somewhat different mecha-
nisms at play in the two systems.
Another striking feature of the IKMV short-term model
is the robust proliferative response induced after NF-κB
activation. Mechanistically, this could be mediated by dir-
ect binding of NF-κB to the promoter of cell-cycle media-
tors, as it has been shown to transcriptionally regulate
cyclin d1[38]. However, we did not find a significant in-
crease in cyclin d1 mRNA expression in IKMV vs. control
glands after the three day dox treatment (data not shown).
We did observe changes in two other cell cycle mediators:
cyclin b1 and p18INK4c. As noted earlier, both an increase
in cyclin b1 and a decrease in p18INK4c have been associ-
ated with pro-tumorigenic changes in the breast. No study
has noted the presence of an NF-κB consensus binding site
in either of these genes’ promoters. Nevertheless, some re-
ports indicate that p65 (and other family members) can
bind to numerous sites other than the recognized consen-
sus sequence, such as Alu-repetitive elements in DNA. Via
CHIP analysis, it was shown that NF-κB bound the
p18INK4c promoter, which contains these Alu-repeats, fol-
lowing viral infection of Hela cells [39]. Continued studies
of how NF-κB can directly regulate expression of numer-
ous cell cycle related genes is warranted, given these find-
ings. In addition, proliferation in the IKMV ducts could be
induced through an indirect mechanism, mediated by NF-
κB-driven production of pro-inflammatory factors. In-
creased expression of both TNF-α and Cox-2 was apparent
in the IKMV tissue. TNF-α has been shown to promote
anchorage independent growth and invasion in mammary
epithelial cells, and overexpression of Cox-2 in mammary
epithelium is sufficient to induce hyperplastic growth of
virgin ducts [30, 31]. Likely, a combination of both direct
and indirect mechanisms leads to proliferation and hyper-
plastic growth in the IKMV ducts.
We determined that aberrant NF-κB activation leads
to decreased expression of hormone receptors and other
markers of mammary epithelial differentiation such as
Elf5 and CSN2. This is consistent with our previous re-
port of a dramatic decrease in CSN2 mRNA expression
and protein levels upon NF-κB activation in lactating
mammary glands [12]. It was also previously shown that
constitutive activation of RANK in the mammary epithe-
lium can lead to decreased ELF5 expression [40]. These
observed decreases in markers of epithelial differenti-
ation following NF-κB activation are consistent with re-
ports that NF-κB can function to reprogram mammary
epithelium, leading to epithelial to mesenchymal transi-
tion (EMT) [41]. We did not detect significant mRNA
changes in classic indicators of EMT such as Vimentin,
Zo-1, E-cadherin, or N-cadherin, in the IKMV tissue
(data not shown), but it is possible that these types of
changes may be more apparent at other time points.
We observed two additional clinical markers of tumori-
genesis within the hyperplastic IKMV ducts: infiltration of
macrophages and the up-regulation and mislocalization of
MUC1. Macrophage infiltration and CCL2 expression are
correlated with poor prognosis and metastasis in human
breast cancer [42, 43]. It has been shown that NF-κB acti-
vation in the mammary epithelium enhances macrophage
recruitment to the site of primary mammary tumors in
both the polyoma middle T and Erb2 oncogene-driven
mouse mammary tumor models [16, 18]. In the current
study, we find that NF-κB activation, in the absence of
any oncogenic mutation, results in significant macro-
phage infiltration into the ducts. These immune cells
are likely acting in an “M1” role initially, responding to
the inflammatory signals as they would to an infection. It
will be interesting in future studies to parse the individual
sub-classes of macrophages that are recruited to the mam-
mary ducts and determine whether their phenotype may
become more pro-tumor, or “M2”, with time.
MUC1 expression is a topic of great interest in a variety
of cancer types, and particularly in breast. It is overex-
pressed in 90 % of human breast cancers, and the secreted
form can be detected in the serum of many patients, even
those with non-metastatic disease [44]. Thus, it is actively
being pursued as a serum bio-marker for early detection.
In a previous study, overexpression of the MUC1 cyto-
plasmic domain in mouse mammary tissue resulted in
hyper-branched, hyperplastic ducts with an increased
number of terminal end buds [45]. Activation of NF-κB is
one downstream effect of MUC1 signaling, and may have
been contributing to the hyperplastic phenotype of that
model. In addition, it has been suggested that MUC1 and
p65 participate in an auto-inductive loop, as each has been
shown to increase expression and/or signaling of the other
[33]. Once MUC1 becomes overexpressed and reposi-
tioned along the entire cell membrane, it can activate a
number of receptor tyrosine kinases, most notably epi-
dermal growth factor receptor (EGFR) [46]. It can also
bind to beta-catenin and play a role in activating its
downstream target gene targets [45]. Whether MUC1
signaling plays a critical role in the IKMV phenotype re-
mains to be determined. Inhibitors of MUC1 are being de-
veloped, which could be combined with our model in
future studies to answer this intriguing question [47, 48].
Upon pathological review, we found that the IKMV le-
sions meet the criteria for the diagnosis of low-grade
DCIS [49]. The rate of diagnosis of DCIS in American
women has increased due to mammography, and it is cur-
rently being debated how aggressively these lesions should
be treated. Some argue for minimal treatment, citing that
DCIS has been found at autopsy, and thus may never
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progress to a life-threatening condition in a subset of
women [50]. However, one retrospective study estimated
that 28 % of women treated with biopsy-only for DCIS will
develop invasive carcinoma in a follow-up period of ap-
proximately 15 years, suggesting that more aggressive
treatment is warranted [51]. In the absence of definitive
markers of whether the disease will progress beyond DCIS,
the frequently suggested treatment is mastectomy or lump-
ectomy followed by radiation therapy. This strategy ap-
pears highly effective with an extremely high percentage of
such patients surviving ten years later. However, these
women have then undergone the same aggressive treat-
ment as would be proposed for invasive disease. It remains
unclear what additional factors may lead the contained le-
sions into becoming invasive and metastatic as opposed to
remaining as DCIS. This is a critical area for research, and
future studies using the IKMV model could yield import-
ant insights into what physiological and environmental fac-
tors combine with inflammatory signaling to promote
malignancy in the breast.
Conclusion
Our model underscores the previously unappreciated ef-
fects of short term, aberrant activation of NF-κB signaling
in developmentally normal mammary epithelium. While
prolonged inflammatory signaling is recognized as a risk
factor for tumorigenesis, we now show that even a short
pulse of NF-κB hyper-activation can lead to pre-malignant
changes in the breast. Similar changes in architecture and
molecular signaling could be occurring in human breast
tissue after acute infection, injury, or stress. Thus, inhib-
ition of NF-κB signaling following acute inflammation or
the initial signs of hyperplastic growth could represent an
important opportunity for breast cancer prevention.
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Additional file 1: Gating strategy for FLOW cytometry data in
Fig. 7b. An average of 100,000 events were counted for each sample. To
start, all samples were taken through the first three gates (top, labeled 1, 2,
3), which excluded artifacts that were not single-cells based on forward and
side scatter. From there, DAPI stain was used to determine viability (gate 4).
All DAPI negative cells were carried to gate 5, where cells were split into
CD45 positive and CD45 negative populations. The CD45 positive
population was then gated using F4/80 on the x axis and CD45 on the y
axis (gate 6). Circles indicate CD45 + F4/80+ cells. Values for the graph in
Fig. 7b were obtained by taking the total number of CD45+F4/80+ cells
counted for each sample and dividing that value by the total number of
viable cells counted in the sample (DAPI negative). (PDF 309 kb)
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